Theravance Biopharma (TBPH) Competitors $8.28 +0.04 (+0.49%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TBPH vs. ANNX, PLRX, SNDX, DVAX, HROW, RCKT, XNCR, RCUS, EVO, and ARDXShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Annexon (ANNX), Pliant Therapeutics (PLRX), Syndax Pharmaceuticals (SNDX), Dynavax Technologies (DVAX), Harrow (HROW), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Arcus Biosciences (RCUS), Evotec (EVO), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical preparations" industry. Theravance Biopharma vs. Annexon Pliant Therapeutics Syndax Pharmaceuticals Dynavax Technologies Harrow Rocket Pharmaceuticals Xencor Arcus Biosciences Evotec Ardelyx Annexon (NASDAQ:ANNX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do analysts rate ANNX or TBPH? Annexon presently has a consensus price target of $15.80, suggesting a potential upside of 117.03%. Theravance Biopharma has a consensus price target of $13.75, suggesting a potential upside of 66.06%. Given Annexon's stronger consensus rating and higher possible upside, analysts clearly believe Annexon is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has higher earnings & valuation, ANNX or TBPH? Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$134.24M-$1.23-5.92Theravance Biopharma$57.42M7.05-$55.19M-$0.92-9.00 Which has more volatility & risk, ANNX or TBPH? Annexon has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Does the media refer more to ANNX or TBPH? In the previous week, Theravance Biopharma's average media sentiment score of 1.00 beat Annexon's score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Annexon Neutral Theravance Biopharma Positive Do institutionals and insiders believe in ANNX or TBPH? 99.1% of Theravance Biopharma shares are held by institutional investors. 12.7% of Annexon shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ANNX or TBPH more profitable? Annexon has a net margin of 0.00% compared to Theravance Biopharma's net margin of -73.61%. Theravance Biopharma's return on equity of -21.29% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -44.68% -38.02% Theravance Biopharma -73.61%-21.29%-11.94% Does the MarketBeat Community favor ANNX or TBPH? Theravance Biopharma received 291 more outperform votes than Annexon when rated by MarketBeat users. However, 75.76% of users gave Annexon an outperform vote while only 62.80% of users gave Theravance Biopharma an outperform vote. CompanyUnderperformOutperformAnnexonOutperform Votes5075.76% Underperform Votes1624.24% Theravance BiopharmaOutperform Votes34162.80% Underperform Votes20237.20% SummaryAnnexon and Theravance Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$403.12M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-9.0010.05116.1015.23Price / Sales7.05400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book1.935.594.775.07Net Income-$55.19M$153.56M$119.06M$225.46M7 Day Performance-3.16%0.13%0.80%0.37%1 Month Performance0.85%15.23%5.65%3.57%1 Year Performance-15.34%41.14%36.75%29.43% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma2.5279 of 5 stars$8.28+0.5%$13.75+66.1%-15.6%$405.06M$57.42M-9.00359Positive NewsGap UpANNXAnnexon1.4361 of 5 stars$7.32-2.9%$15.80+115.8%+203.3%$796.63MN/A-5.9560PLRXPliant Therapeutics3.8911 of 5 stars$14.07-2.4%$40.57+188.4%-2.2%$876.15M$1.58M-4.5590SNDXSyndax Pharmaceuticals4.0313 of 5 stars$18.86-0.3%$35.90+90.3%+36.4%$1.61B$139.71M-5.58110Upcoming EarningsDVAXDynavax Technologies4.5743 of 5 stars$11.85-1.7%$23.67+99.7%-16.5%$1.58B$232.28M107.74408Upcoming EarningsHROWHarrow3.3678 of 5 stars$45.06+1.4%$56.67+25.8%+239.3%$1.58B$130.19M-47.43182Short Interest ↓Positive NewsRCKTRocket Pharmaceuticals4.3151 of 5 stars$16.65-1.9%$51.75+210.8%-10.6%$1.54BN/A-5.97240Upcoming EarningsXNCRXencor4.0946 of 5 stars$21.010.0%$34.78+65.5%+21.7%$1.47B$168.34M-7.27280Upcoming EarningsRCUSArcus Biosciences2.7196 of 5 stars$15.30-4.4%$33.67+120.0%-2.0%$1.46B$117M-4.95500Upcoming EarningsEVOEvotec2.5238 of 5 stars$3.87-2.3%$5.93+53.3%-54.8%$1.40B$845.74M0.005,061Upcoming EarningsARDXArdelyx4.1613 of 5 stars$5.87-0.3%$11.67+98.8%+54.6%$1.39B$124.46M-21.74267Analyst ForecastInsider SellingOptions VolumeAnalyst RevisionGap UpHigh Trading Volume Related Companies and Tools Related Companies ANNX Alternatives PLRX Alternatives SNDX Alternatives DVAX Alternatives HROW Alternatives RCKT Alternatives XNCR Alternatives RCUS Alternatives EVO Alternatives ARDX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TBPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
